

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SUNSHINE LAKE PHARMA CO., LTD.**

**廣東東陽光藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

## **POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING**

Reference is made to the circular of Sunshine Lake Pharma Co., Ltd. (the “**Company**”) dated 28 November 2025 (the “**Circular**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

### **POLL RESULTS OF THE EGM**

The EGM was held on Tuesday, 16 December 2025 at Conference Room, 3/F, Sales Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC. The EGM was duly and validly convened in accordance with the Company Law and other relevant laws and regulations of the PRC, the Hong Kong Listing Rules and the Articles of Association.

On the date of the EGM, the total number of Shares issued by the Company was 576,656,047 Shares, comprising a total of 463,943,215 Domestic Shares and a total of 112,712,832 H Shares issued, all of which conferred upon their holders the right to attend the EGM and to vote for, against or abstain from voting on the resolutions proposed at the EGM. There were no Treasury Shares held by the Company (including any Treasury Shares held or deposited with the Central Clearing and Settlement System). Shareholders (either in person or by proxy) present at the EGM held 441,920,087 Shares carrying voting rights, representing approximately 76.6350% of the total number of issued Shares carrying voting rights.

No shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the EGM. There were no Shares entitling the holder to attend and abstain from voting in favour of the proposed resolutions at the EGM pursuant to Rule 13.40 of the Hong Kong Listing Rules. No shareholder has indicated in the EGM Circular that they intend to vote against or abstain from voting on the proposed resolutions.

The proposed resolutions were voted on by poll. The Company's H Share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the counting of votes at the EGM. Two shareholder representatives and one supervisor of the Company also acted as scrutineers for the vote-taking and counting.

All the Directors have attended the EGM.

The poll results of the EGM are as follows:

Special Resolutions		Number of votes and percentage of total votes (%)		
		For	Against	Abstain
1	To consider and approve the granting of a general mandate to the Board to repurchase issued Shares not exceeding 10% of the total issued Shares (excluding Treasury Shares) of the Company as at the date of passing this resolution, during the Relevant Period.	441,920,087 (100.0000%)	0 (0.0000%)	0 (0.0000%)
2	Subject to the passing of resolution no.1, to extend the General Issue Mandate granted to the Board on 5 September 2025 by the number of Shares repurchased under resolution no. 1.	437,547,591 (99.0106%)	4,372,496 (0.9894%)	0 (0.0000%)
3	To consider and approve the Resolution on the Amendments to the Articles of Association.	441,920,087 (100.0000%)	0 (0.0000%)	0 (0.0000%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the above resolutions, these resolutions were duly passed as special resolutions.

By order of the Board  
**Sunshine Lake Pharma Co., Ltd.**  
**Dr. ZHANG Yingjun**  
*Chairman of the Board*

Dongguan, the PRC  
16 December 2025

*As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.*